Willow is a 100% online, medically supervised weight loss program prescribing GLP-1 medications — semaglutide and tirzepatide — through US licensed physicians. Plans start at $299/month with no insurance required, and many patients lose up to 20% of their body weight.
This review covers how the Willow program works, what medications it offers, and what clinical trial data says about expected outcomes. Semaglutide produced 14.9% average body weight loss at 68 weeks in the STEP trials; tirzepatide reached 22.5% at 72 weeks in SURMOUNT-1. User reviews highlight program convenience and physician access. Common complaints involve GI side effects during dose escalation and the cost for uninsured patients.
By the end, you will know whether Willow is a legitimate telehealth provider, who qualifies, what the real side effect profile looks like, and how it compares in cost to alternative GLP-1 programs.
What Is Willow Weight Loss?
Willow is a 100% online, medically supervised weight loss program that prescribes GLP-1 medications — semaglutide and tirzepatide — personalized to each patient’s body and goals by licensed US physicians. No insurance is required. The program runs on a transparent monthly subscription starting at $299.
Here’s how it works: Willow physicians review each patient’s health history, weight loss goals, and individual needs before determining whether GLP-1 treatment is appropriate and safe. Both injectable and oral options are available. The physician makes the medication selection based on clinical fit — not a one-size algorithm.
Many Willow patients lose up to 20% of their body weight, with visible results in just a few months. A physician and care team provide guidance throughout the treatment journey. This is not a supplement company — it’s a regulated telehealth medical practice prescribing FDA-approved drugs.
How Does the Willow Program Work?
Willow follows a three-step process: patients complete a short online health assessment, a licensed physician reviews the submission and creates a personalized treatment plan, and GLP-1 medication is prescribed for home delivery if the patient is eligible.
Same-day prescriptions and free 2-day shipping are included in every plan. After starting treatment, patients can message their physician anytime through the patient portal for dose adjustments, side effect management, or ongoing support. Access to the care team is part of the monthly subscription — not a separate charge.
What GLP-1 Medications Does Willow Offer?
Willow offers semaglutide in both injectable and oral tablet form, as well as tirzepatide in injectable form — with the physician selecting the appropriate formulation based on patient health history and individual weight loss goals.
Tirzepatide is a dual GIP/GLP-1 receptor agonist — a newer mechanism that produces stronger weight loss outcomes than semaglutide alone in head-to-head comparisons. Patients who have not responded adequately to semaglutide or who have specific metabolic profiles may be better candidates for tirzepatide under physician guidance.
What Are the Ingredients in Willow’s Medications?
Semaglutide is a GLP-1 receptor agonist that mimics the naturally occurring GLP-1 gut hormone — signaling the brain to reduce appetite, slowing gastric emptying, and stimulating insulin release in response to meals. It is the active compound in Wegovy (weight management) and Ozempic (diabetes).
Tirzepatide is the first dual GIP and GLP-1 receptor agonist. It activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) pathways simultaneously. This dual mechanism amplifies appetite suppression and metabolic response beyond what GLP-1 activation alone achieves.
Both compounds are FDA-approved drugs — not dietary supplements. Semaglutide is available as Wegovy and Ozempic. Tirzepatide is available as Mounjaro and Zepbound. Willow prescribes these within a medically supervised framework, which is a fundamentally different context than buying a supplement online.
Willow Medication Options:
| Medication | Class | Forms Available | FDA Brand |
|---|---|---|---|
| Semaglutide | GLP-1 agonist | Injectable + oral tablet | Wegovy / Ozempic |
| Tirzepatide | Dual GIP/GLP-1 agonist | Injectable | Zepbound / Mounjaro |
Does Semaglutide Work for Weight Loss?
Yes. Semaglutide produced an average of 14.9% body weight loss at 68 weeks in the STEP clinical trial program, with some participants exceeding 20% — results significantly greater than placebo across all primary endpoints.
The mechanism is well-established. Semaglutide activates GLP-1 receptors in the hypothalamus, reducing hunger signaling at the brain level. This produces measurable reductions in total daily energy intake without requiring willpower-based restriction — a key advantage over caloric deficit diets alone.
Does Tirzepatide Work for Weight Loss?
Yes. Tirzepatide produced up to 22.5% average body weight loss at 72 weeks in the SURMOUNT-1 trial at the 15 mg maximum dose — the largest weight reduction ever recorded in a randomized controlled weight loss trial at the time of publication.
Head-to-head comparisons consistently show tirzepatide outperforms semaglutide for weight reduction. The dual GIP/GLP-1 mechanism appears to amplify both appetite suppression and metabolic effects. For a participant starting at 220 pounds (99.8 kg), 22.5% weight loss equals approximately 50 pounds (22.7 kg) lost.
How Much Weight Can You Lose With Willow?
Willow states many patients lose up to 20% of their body weight, with visible results in just a few months — an outcome aligned with clinical trial data for semaglutide and within the lower range of tirzepatide outcomes from SURMOUNT-1.
In practice, outcomes vary. Clinical data shows a range from 5% to over 20% body weight loss across patient populations over 12-18 months, depending on medication dose, dietary adherence, activity level, and individual metabolic factors. Not every patient will reach the 20% ceiling — but most see meaningful change.
Reduced appetite is typically the first noticeable effect, often within 1-2 weeks of starting treatment. Measurable weight loss usually appears by weeks 4-8. Significant reductions of 10% or more become achievable by month 4-6 at therapeutic doses with consistent adherence.
Expected Weight Loss by Timeframe:
| Timeframe | Typical Outcome | Key Milestone |
|---|---|---|
| Weeks 1-2 | Reduced appetite noticeable | Behavioral changes begin |
| Weeks 4-8 | 2-4% body weight loss | Scale movement visible |
| Months 4-6 | 8-12% body weight loss | 10%+ threshold reached |
| 12-18 months | 15-22%+ body weight loss | Maximum clinical benefit |
What Do Clinical Trials Say About GLP-1 Weight Loss?
The STEP clinical trial program showed semaglutide 2.4 mg produced an average of 14.9% body weight loss at 68 weeks alongside lifestyle intervention — a result significantly greater than placebo and greater than any prior approved weight loss pharmacotherapy at the time.
SURMOUNT-1 pushed outcomes further: tirzepatide 15 mg produced 22.5% average body weight loss at 72 weeks. For context — that’s equivalent to losing roughly 50 pounds (22.7 kg) from a 220-pound (99.8 kg) starting weight. These are landmark findings in the history of obesity pharmacotherapy.
How Fast Do Willow Patients See Results?
Reduced appetite is typically the first change, often appearing within 1-2 weeks of starting GLP-1 medication — the appetite reduction then drives the behavioral changes that produce measurable weight loss in the weeks that follow.
Willow states visible results appear in just a few months. Clinical data backs this: 4-6% body weight loss by weeks 8-12, with 10%+ outcomes becoming achievable by month 4-6 at therapeutic doses. The early months are about building momentum — the larger outcomes accumulate over the full treatment course.
What Do Willow Weight Loss Reviews Say?
Willow reviews are generally positive. Users most frequently cite the convenience of telehealth access to GLP-1 medications, responsive physician care through the patient portal, and meaningful weight loss outcomes as the program’s standout strengths.
Independent comparisons of Willow vs Hers — a competing telehealth provider — conclude both are legitimate platforms, with Willow preferred specifically for GLP-1-focused weight management. Users who need broader women’s health services tend toward Hers. For weight loss specifically, reviewers favor Willow’s dedicated focus.
What Are the Positive Experiences With Willow?
Patients report meaningful weight loss of 10-20% of body weight over several months, alongside dramatically reduced appetite that makes caloric restriction feel effortless compared to prior diet attempts — a consistently cited departure from willpower-dependent approaches.
The program’s convenience also draws strong praise. Fully online onboarding, same-day prescriptions, free 2-day shipping, and physician portal access remove the friction of in-person clinic visits. Users describe the care team as responsive and the physician communication as genuinely personalized.
What Are the Common Complaints About Willow?
The most common complaints involve GI side effects from the medications — specifically nausea, constipation, and fatigue during dose escalation — though reviewers note these are known GLP-1 medication effects rather than program-specific failures.
Cost is the other major friction point. At $299+ per month without insurance coverage, the program is inaccessible for many prospective users. State availability restrictions add a second barrier — patients outside Willow’s current service area cannot enroll regardless of interest or eligibility.
Is Willow Legit?
Yes. Willow prescribes FDA-approved GLP-1 medications through US licensed physicians under standard medical practice laws — pricing is transparent with no hidden fees, and the platform operates as a regulated telehealth provider, not an unregulated supplement company.
Independent reviewer comparisons of Willow and Hers conclude both platforms are legitimate GLP-1 telehealth providers. Willow is the preferred choice for patients seeking a GLP-1-specific weight management program. The prescription model, physician oversight, and FDA-approved drugs distinguish Willow clearly from the supplement market.
Is Willow FDA Approved or Regulated?
The medications Willow prescribes — semaglutide and tirzepatide — are FDA-approved drugs with extensive clinical trial data. Willow itself operates as a telehealth platform regulated under state medical licensing laws and telehealth practice regulations.
US licensed physicians on the Willow platform operate under state medical board oversight. Prescriptions follow standard medical practice laws. This regulatory context is fundamentally different from unregulated supplement companies — and the distinction matters for both safety and outcome credibility.
What Are the Side Effects of Willow’s Medications?
The most common side effects of Willow’s GLP-1 medications are nausea, vomiting, diarrhea, constipation, and abdominal pain — all gastrointestinal in nature and most pronounced during dose escalation, typically resolving as the body adjusts to each dose level.
To be clear, serious risks also exist. Both semaglutide and tirzepatide carry a risk of medullary thyroid carcinoma (MTC) in susceptible patients. Pancreatitis is a rare but serious risk. Willow physicians screen for contraindications before prescribing and monitor patients throughout the program.
Gradual dose escalation is the primary tool for managing GI side effects. Willow’s physician portal allows real-time dose adjustment and side effect support — a meaningful advantage over programs that prescribe without ongoing clinical contact.
Common GLP-1 Side Effects (Semaglutide and Tirzepatide):
- Nausea (most common, especially during dose escalation)
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Fatigue (commonly reported in first weeks)
Who Should Avoid the Willow Program?
Patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2) should not use GLP-1 medications and are not eligible for the Willow program — Willow physicians screen for these conditions during the onboarding health review.
Pregnant or breastfeeding individuals, patients with active pancreatitis, and those with certain severe gastrointestinal conditions are typically excluded from GLP-1 treatment. The online assessment and physician review process identifies these exclusions before any prescription is issued.
How Much Does Willow Cost?
Willow plans start at $299 per month and include doctor oversight, GLP-1 medication, same-day prescriptions, free 2-day shipping, and ongoing care through the patient portal — no insurance required, no hidden fees.
Willow does not work with insurance for medication coverage. The monthly cost covers the full program. For patients who previously faced insurance denials for GLP-1 medications — a common experience, particularly for weight management indications — this transparent, no-insurance model removes a significant barrier to access.
Is Willow Worth the Price?
For patients who qualify medically, yes. At $299/month for FDA-approved GLP-1 medications with physician supervision, Willow delivers a clinically grounded weight loss program — and patients who lose 15-20% of body weight achieve health outcomes that carry value well beyond the monthly cost.
Comparable in-clinic GLP-1 programs often cost significantly more when accounting for consultation fees, monitoring visits, and medication markup. Willow’s bundled telehealth model offers competitive value — particularly for patients without insurance coverage who would otherwise face full retail pricing for GLP-1 medications.
Should You Try Eat Proteins Alongside Willow?
Eat Proteins provides protein-forward nutrition coaching that directly amplifies GLP-1 outcomes — because clinical data consistently shows medication plus dietary intervention outperforms medication alone, and protein intake is the critical nutritional variable for preserving lean muscle during rapid weight loss.
GLP-1 medications like semaglutide and tirzepatide produce rapid weight loss that can include muscle loss alongside fat loss. High protein intake — the cornerstone of the Eat Proteins approach — is the primary nutritional strategy for preserving lean mass during caloric restriction. Protecting that muscle preserves your metabolic rate and long-term results.
So here’s the play: Willow gives you the medical intervention. Eat Proteins gives you the nutritional framework that makes it stick. Our coaches help you build habits that sustain your results when treatment eventually ends. The two approaches work together — not in competition.